Methods and compositions for generating hematopoietic cells
Maturation signals provided via cyclic adenosine monophosphate (cAMP)/ E xchange p roteins a ctivated by c AMP (Epac) signaling during in vitro generation of blood cells from reprogrammed cells or pluripotent stem cells achieve superior function of hematopoietic cells differentiated from stem cells. The cAMP/Epac signaling enables an increased efficiency of production of precursor to blood and to blood cells. These generated blood cells can be utilized for therapeutics, treatments, disease prevention, drug discovery, personalized medicine, regenerative medicine, cell and tissue generation, universal donor banks and related methods and compositions.
1. A method of producing hematopoietic cells, comprising:
obtaining cells that are capable of generating hematopoietic cells;
culturing said cells under conditions that specify them towards the hematopoietic lineage and/or through hematopoietic lineages;
further culturing said cells in a medium that comprises an activator of cyclic adenosine monophosphate (cAMP) or cAMP-Epac axis, wherein Epac refers to Exchange proteins activated by cAMP, thereby obtaining hematopoietic cells; and
selectively removing macrophages during culturing of said cells in the medium.
2. The method of claim 1 , further comprising culturing or expanding the population of the cells prior to or after culturing said cells under conditions that specify them towards the hematopoietic lineage and/or through hematopoietic lineages.
3. The method of claim 1 , wherein embryoid bodies are not formed.
4. The method of claim 1 , wherein the activator of cAMP reduces oxidative stress on the cells.
5. The method of claim 4 , wherein oxidative stress is further reduced by either controlling the environmental oxygen level, or culturing the cells in the presence of redox state modifiers.
6. The method of claim 3 , wherein the activator of cAMP enhances expression of the CXCR4 protein on the surface of the cells.
7. The method of claim 1 , wherein the cells are selected from the group consisting of pluripotent stem cells, embryonic stem cells, induced pluripotent stem cells (iPSC), directly reprogrammed somatic cells with hemogenic potential, hemogenic endothelial cells, precursors of hematopoietic cells, and any combination thereof.
8. The method of claim 1 , wherein the cAMP and/or cAMP-Epac axis activator is selected from the group consisting of forskolin, IBMX, norepinephrine, epinephrine, salmeterol, isoproterenol, db-cAMP, 8-Br-cAMP, Bucladesine, 6-Bnz-cAMP, cAMPS -Sp, triethylammonium salt, N6-Monobutyryladenosine 3′:5′-cyclic monophosphate sodium salt, 8-Bromoadenosine 3′,5′-cyclic monophosphate, Adenosine 3′,5′-cyclic monophosphate, CW008 (4-Fluoro-N-[5-fluoro-6-(5-methoxypyrazolo[1,5-a]pyridin-3-yl)-1H-pyrazolo[3,4-b]pyridin-3-yl]benzamide), Cholera toxin, Prostaglandins, or any combination thereof.
9. The method of claim 1 , wherein the activator of the cAMP-Epac axis is a direct activator of Epac.
10. The method of claim 1 , wherein the medium excludes an inhibitor of Epac.
11. The method of claim 1 , wherein the medium further comprises an inhibitor of macrophage development.
12. A method of producing hematopoietic cells, comprising:
obtaining cells that are capable of generating hematopoietic cells;
culturing said cells under conditions that specify them towards the hematopoietic lineage and/or through hematopoietic lineages;
furthur culturing said cells in a medium that comprises an activator of cyclic adenosine monophosphate (cAMP) or cAMP-Epac axis, wherein Epac refers to Exchange proteins activated by cAMP, thereby obtaining hematopoietic cells;
reducing oxidative stress by either controlling the environmental oxygen level or culturing the cells in the presence of redox state modifiers; and
wherein embryoid bodies are not formed.
13. The method of claim 12 , further comprising culturing or expanding the population of the cells prior to or after culturing said cells under conditions that specify them towards the hematopoietic lineage and/or through hematopoietic lineages.
14. The method of claim 12 , wherein the activator of cAMP reduces oxidative stress on the cells.
15. The method of claim 12 , wherein the activator of cAMP enhances expression of the CXCR4 protein on the surface of the cells.
16. The method of claim 12 , wherein the cells are selected from the group consisting of pluripotent stem cells, embryonic stem cells, induced pluripotent stem cells (iPSC), directly reprogrammed somatic cells with hemogenic potential, hemogenic endothelial cells, precursors of hematopoietic cells, and any combination thereof.
17. The method of claim 12 , wherein the cAMP and/or cAMP-Epac axis activator is selected from the group consisting of forskolin, IBMX, norepinephrine, epinephrine, salmeterol, isoproterenol, db-cAMP, 8-Br-cAMP, Bucladesine, 6-Bnz-cAMP, cAMPS-Sp, triethylammonium salt, N6-Monobutyryladenosine 3′:5′-cyclic monophosphate sodium salt, 8-Bromoadenosine 3′,5′-cyclic monophosphate, Adenosine 3′,5′-cyclic monophosphate, CW008 (4-Fluoro-N-[5-fluoro-6-(5-methoxypyrazolo[1,5-a]pyridin-3-yl)-1H-pyrazolo[3,4-b]pyridin-3-yl]benzamide), Cholera toxin, Prostaglandins, or any combination thereof.
18. The method of claim 1 , wherein the activator of the cAMP-Epac axis is a direct activator of Epac.
19. The method of claim 12 , wherein the medium excludes an inhibitor of Epac.
20. The method of claim 12 , wherein the medium further comprises an inhibitor of macrophage development.